27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- SVB Leerink maintains an Outperform rating on Relmada Therapeutics Inc (NASDAQ:RLMD) shares as the Human Liability Potential study data was about "as good as we could have hoped for," with no evidence of abuse potential.
- Analyst Marc Goodman believes this data should give confidence to the investment community that REL-1017 will probably end up as a Schedule IV or V, which would be great news.
- Several experts confirmed that the data was supportive of this low scheduling on the conference call, Goodman adds.
- Given the weak stock performance recently, the analyst would expect Relmada to bounce back and move into the $35-$40 range in the near term.
- Truist raised the price target on Relmada to $90 from $75 and kept a Buy rating (upside of more than 250%).
- Analyst Joon Lee notes that the HAP study comparing REL-1017 against IV ketamine is expected to start in 2H21.
- The management expects similar likability scores for REL-1017, while IV Ketamine is likely to yield a likability score over 65, implying that 25mg and 75mg will likely separate with statistical significance.
- Price Action: RLMD shares are down 3.86% at $24.15 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!